Stifel analyst Jonathan Block lowered the firm’s price target on Inspire Medical (INSP) to $100 from $140 and keeps a Hold rating on the shares. The firm, which says its previously expressed GLP-1 concern is playing out, tells investors that a “couple of our key Inspire Medical concerns have taken hold,” adding that it believes inventory “could be the next shoe to drop.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical downgraded to Hold from Buy at Jefferies
- Inspire Medical price target lowered to $90 from $125 at Truist
- Inspire Medical price target lowered to $150 from $180 at RBC Capital
- Inspire Medical Systems Unveils Positive Data for Inspire V
- Inspire Medical publishes Inspire V data at ISSS/AAO-HNS meetings